Close Menu

ASCO

Researchers affiliated with breast cancer charity the Side-Out Foundation presented pilot study data this week at the American Society of Clinical Oncology's annual meeting suggesting proteomics' potential as a tool in personalizing therapy for breast cancer.

The American Society of Clinical Oncology held its annual meeting June 1-5 in Chicago.
The following are abstracts presented at the meeting focused on pharmacogenomically guided treatment strategies.

Originally published July 17.

A group of researchers led by Oleg Gluz of the West German Study Group, and including employees of Genomic Health, has shared data from the phase III WSG-Plan B trial showing that high-risk recurrence scores obtained by Genomic Health's Oncotype DX test predict high risk as measu

The American Society of Clinical Oncology is in the midst of developing a rapid-learning system that aims to connect physicians’ practices, measure their performance and quality of care, and advance best practices by providing doctors real-time decision support.

The American Society of Clinical Oncology held its annual meeting June 1 - 5 in Chicago. The following are abstracts presented at the meeting focused on the application of molecular diagnostics to cancer prognosis.

NEW YORK (GenomeWeb News) – If genetic tests that predict individual cancer risk are not reimbursed by health insurers, some people who have received referrals for those tests may opt not to take them, according to a new study from Fox Chase Cancer Center.

Data from the study showed that Rosetta's array-based Mets 2 test has 88 percent concordance with clinical presentation and pathology, exceeding the accuracy of the PCR-based version of the test.

The company hopes the positive safety profile of the drug will entice industry partners interested in licensing siRNA delivery systems, Silence's CEO said.

Pages